DFine awarded US Department of Veterans Affairs five-year contract for StabiliT vertebral augmentation system


DFine, developer of minimally invasive radiofrequency targeted therapies for the treatment of vertebral pathologies, announced today the award of a five-year Federal Supply Schedule (FSS) contract from the US Department of Veterans Affairs. 

According to the terms of the contract, DFine will supply the StabiliT radiofrequency targeted vertebral augmentation (RF-TVA) system and all related products to treat vertebral compression fractures to the Veterans Affairs system, representing 950 facilities throughout the USA.

“We are proud to have been selected by Veterans Affairs to provide DFine’s innovative StabiliT system to treat patients who are suffering from vertebral compression fractures,” said Kevin Mosher, DFine’s CEO. “We appreciate the tremendous sacrifice our military personnel make and believe these individuals and their families should have access to RF-TVA, the most advanced, targeted therapy for the treatment of vertebral compression fractures.”

According to the US Department of Veteran Affairs, an estimated 700,000 vertebral compression fractures occur annually in the United States, and more than 80% of the patients who present are 65 years and older.

About StabiliT and radiofrequency targeted vertebral augmentation (RF-TVA)

The StabiliT vertebral augmentation system is the latest advancement in the treatment of vertebral compression fractures. During the RF-TVA procedure, a small tube is placed into the fractured vertebra and a cavity is created. Ultra-high viscosity StabiliT ER bone cement fills the cavity and permeates the surrounding bone to stabilise the fracture.

With StabiliT, physicians are able to navigate within the vertebral body to target the spinal fracture with greater precision and control, while also sparing the bone— two unique benefits of RF-TVA over older, conventional therapies such as balloon kyphoplasty. The RF-TVA procedure typically takes 30−40 minutes to complete under local anesthesia. Patients report significant and lasting back pain relief, significant improvement in mobility and quality of life, and often return to daily activities soon after the procedure.

DFine received FDA’s 510(k) clearance and commercially introduced the StabiliT system in 2008. To date, more than 12,000 spinal fractures have been treated with StabiliT worldwide.